Asia Insurance Post
  • Home
  • Articles
  • Blog
  • Data
  • Facts
  • Editorial
  • Interviews
Select Page

India should adopt risk-based approach not blanket bans to contain Covid: WHO India head

by AIP Online Bureau | Jan 18, 2022 | Eco/Invest/Demography, Health, Indian News, Pandemic, Risk Management

”WHO does not recommend a blanket travel ban, nor complete restriction of people’s movement. In many ways, such blanket approaches can be counterproductive. India with its diversity in population distribution and geographic spread, the risk-based approach...

Sanctioned Rs 50,000 compensation to each of 68,370 claims for COVID-19 deaths: Guj govt tells SC

by AIP Online Bureau | Jan 18, 2022 | Data, Eco/Invest/Demography, Health, Pandemic, Policy

The state government had said that it received 89,633 claim forms (applications) seeking compensation for COVID-19 deaths, out of which 58,840 claims have been settled and the amount has been disbursed to applicants New Delhi: The Gujarat government has told the...

IRDAI reduces general insurers’ obligatory cession for GIC Re to 4 % from 5 % in FY 2023

by AIP Online Bureau | Jan 17, 2022 | Indian News, Intermediaries, Non-Life, Regulation, Reinsurance

The approximate size of the Indian reinsurnace market is around Rs 55,000 cror in FY.2020-21. To begin with, obligatory cession for GIC Re was 10 per cent which was reduced to five per cent afterwards and the foreign reinsurers which are having braches in India are...

Govt seeks applications for a new IRDAI member(Non-Life)

by AIP Online Bureau | Jan 17, 2022 | Health, Indian News, Non-Life, Regulation

TL Alamelu, member(Non-Life), IRDAI will be retiring on May 6,2022 after completing her three-year tenure New Delhi: The government on Monday has asked for applications to appoint a new member (Non-life), in Hyderabad based IRDAI. The current member(Non-Life),TL...

India’s Gennova developing Omicron-specific COVID-19 vaccine

by AIP Online Bureau | Jan 17, 2022 | Health, Indian News, Pandemic

The source said Gennova on Friday separately submitted to India’s drug regulator phase 2 trial data for its original mRNA vaccine candidate. The government said last year that product was found to be “safe, tolerable, and immunogenic” in the...
« Older Entries
Next Entries »

Recent Posts

  • New India honours insurance veteran S.K. Kanwar with ‘Legacy of Excellence Award’
  • Iran expands attacks on Gulf states after US strikes, says Strait of Hormuz closed
  • Bavi hits China, Millions evacuated
  • US eyes steering wheel-free cars
  • Strongest El NiƱo in 75 years, says US Climate Prediction Center

Categories

  • Articles
  • Banking & Bancassurance
  • Blog
  • Breaking News!
  • Briefs
  • Climate, Environment, Renewable Energy
  • Data
  • Disaster & Management
  • Eco/Invest/Demography
  • Editorial
  • Events
  • Facts
  • Features
  • Health
  • Indian News
  • Intermediaries
  • International News
  • Interviews
  • Life
  • Main Menu
  • Non-Life
  • Pandemic
  • Pension & Social Security
  • Policy
  • Regulation
  • Reinsurance
  • Risk Management
  • Simple
  • Technology
  • Trends, Facts
  • Uncategorized
  • Wealth Management/ Philanthropy
  • Workplace/Employee Benefits
  • Home
  • Articles
  • Blog
  • Data
  • Facts
  • Editorial
  • Interviews
  • Eco/Invest/Demography
  • Indian News
  • International News
  • Health
  • Non-Life
  • Pandemic
  • Technology
  • Risk Management
  • Reinsurance
  • Banking & Bancassurance
  • Wealth Management/ Philanthropy